|
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards
|
06 January 2016 |
|
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care
|
05 October 2015 |
|
Genzyme recognizes World MS Day
|
30 May 2012 |
|
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
|
22 January 2012 |
|
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration
|
16 November 2011 |
|
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
|
12 July 2011 |
|
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
|
17 June 2011 |
|
Genzyme Revenues Grow in First-Quarter 2011
|
29 April 2011 |
|
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
|
15 April 2011 |
|
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
|
07 March 2011 |
|
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
|
28 February 2011 |
|
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year
|
16 February 2011 |
|
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence
|
31 January 2011 |
|
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®
|
20 January 2011 |
|
Genzyme Financial Recovery Continues in Fourth Quarter
|
11 January 2011 |
|
Genzyme Statement on Discussions With Sanofi-Aventis
|
10 January 2011 |
|
Genzyme Details Market Potential of Alemtuzumab for MS
|
20 December 2010 |
|
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer
|
13 December 2010 |
|
Genzyme Completes Sale of Genetic Testing Business to LabCorp
|
01 December 2010 |
|
Genzyme Announces Agreement to Sell Diagnostics Business
|
18 November 2010 |